Literature DB >> 19549523

Coinfection with HIV-1 and HCV--a one-two punch.

Arthur Y Kim1, Raymond T Chung.   

Abstract

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, cirrhosis, and death; it is estimated that 180 million persons are infected with HCV worldwide. The consequences of HCV are worse in those who are coinfected with human immunodeficiency virus 1 (HIV-1), which is unfortunately a common scenario because of shared risk factors of the viruses. More studies into effects of HCV/HIV-1 coinfection are needed, but efforts have been hampered by limitations in our understanding of the combined pathogenesis of the 2 viruses. Gaining insight into the mechanisms that underlie the immunopathogenesis of these persistent viral infections could lead to new therapeutic strategies for patients with HCV/HIV-1 coinfection.

Entities:  

Mesh:

Year:  2009        PMID: 19549523      PMCID: PMC3146750          DOI: 10.1053/j.gastro.2009.06.040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  249 in total

1.  Is there a point at which you would recommend discontinuing treatment due to liver toxicity, short of liver failure? What, for instance, would be the numbers to look for with liver enzyme tests? How high is too high? My doctor has said they are seeing more people in their practice die from liver disorders than from the virus itself nowadays. This has me very concerned since I am co-infected with HCV.

Authors:  M S Sulkowski
Journal:  Hopkins HIV Rep       Date:  2001-11

2.  Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells.

Authors:  Y M Mueller; S C De Rosa; J A Hutton; J Witek; M Roederer; J D Altman; P D Katsikis
Journal:  Immunity       Date:  2001-12       Impact factor: 31.745

3.  Protection against persistence of hepatitis C.

Authors:  Shruti H Mehta; Andrea Cox; Donald R Hoover; Xiao-Hong Wang; Qing Mao; Stuart Ray; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

4.  The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

Authors:  V Di Martino; P Rufat; N Boyer; P Renard; F Degos; M Martinot-Peignoux; S Matheron; V Le Moing; F Vachon; C Degott; D Valla; P Marcellin
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

5.  Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.

Authors:  Georg M Lauer; Tam N Nguyen; Cheryl L Day; Gregory K Robbins; Theresa Flynn; Katherine McGowan; Eric S Rosenberg; Michaela Lucas; Paul Klenerman; Raymond T Chung; Bruce D Walker
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfection.

Authors:  Peter M Rosenberg; James J Farrell; Diane R Abraczinskas; Fiona M Graeme-Cook; Jules L Dienstag; Raymond T Chung
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

7.  HLA-Cw*04 and hepatitis C virus persistence.

Authors:  Chloe L Thio; Xiaojiang Gao; James J Goedert; David Vlahov; Kenrad E Nelson; Margaret W Hilgartner; Stephen J O'Brien; Peter Karacki; Jacquie Astemborski; Mary Carrington; David L Thomas
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus.

Authors:  Nadia Alatrakchi; Vincent Di Martino; Vincent Thibault; Brigitte Autran
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

9.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

10.  Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions.

Authors:  Chien-Te K Tseng; Gary R Klimpel
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  82 in total

Review 1.  Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients.

Authors:  Gyongyi Szabo; Samir Zakhari
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

Review 2.  Update on hepatitis C virus-specific immunity.

Authors:  Donatella Ciuffreda; Arthur Y Kim
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

3.  Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; Kaku A Armah; Richard Saitz; Matthew S Freiberg; Jeffrey H Samet; Judith I Tsui
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

4.  Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold.

Authors:  Lun K Tsou; Ginger E Dutschman; Elizabeth A Gullen; Maria Telpoukhovskaia; Yung-Chi Cheng; Andrew D Hamilton
Journal:  Bioorg Med Chem Lett       Date:  2010-02-13       Impact factor: 2.823

5.  HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.

Authors:  M Frías; D Rodríguez-Cano; F Cuenca-López; J Macías; A Gordon; B Manzanares-Martín; J A Pineda; Á Camacho; J Torre-Cisneros; J Peña; A Rivero-Juárez; A Rivero
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

6.  Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui
Journal:  Addiction       Date:  2013-10-24       Impact factor: 6.526

7.  CD4/CD8 ratio is a promising candidate for non-invasive measurement of liver fibrosis in chronic HCV-monoinfected patients.

Authors:  Thijs Feuth; Debbie van Baarle; Karel J van Erpecum; Peter D Siersema; Andy I M Hoepelman; Joop E Arends
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-22       Impact factor: 3.267

8.  Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.

Authors:  Cassandra B Jabara; Fengyu Hu; Katie R Mollan; Sara E Williford; Prema Menezes; Yan Yang; Joseph J Eron; Michael W Fried; Michael G Hudgens; Corbin D Jones; Ronald Swanstrom; Stanley M Lemon
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

9.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users.

Authors:  Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

Review 10.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.